Trial Condition(s):

Bronchiectasis

Inhalation Flow Rate-study

Bayer Identifier:

17607

ClinicalTrials.gov Identifier:

NCT02563197

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.

Inclusion Criteria
- Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)
 - Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory Society criteria
 - Clinically stable in the opinion of the investigator at the time of the study visit.
 - Male and female patients ≥ 18 years of age.
Exclusion Criteria
- Pulmonary exacerbation (as judged by the investigator, based on the clinical condition of the subject and taking into account e.g., febrile infection of the lung, relevant decrease in Forced expiratory volume in the first second (FEV1) value, increased sputum production, sputum purulence, recent hospitalization) at study visit or within the preceding six (6) weeks.
 - History of lung transplant.
 - Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the preceding six (6) weeks before screening.
 - Established diagnosis of bronchial asthma.
 - Established diagnosis of cystic fibrosis.
 - Proof of any relevant medical finding or disease in the last three (3) months which might interfere with participation in the study or patient safety (e.g. pneumothorax, uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction, cerebral vascular accident).
 - A relevant disease that is considered to interfere with the study results is any disease that, except for the impairment of lung function, interferes with the patient’s ability to inhale from the device. For example, COPD per se is usually not considered as a reason for patient exclusion, unless coughing or obliteration of the upper airways with sputum interferes with the patient’s ability to inhale from the device.
 - Relevant surgical history in the last 3 months (e.g., but not limited to abdominal, thoracic, ocular or brain surgery).
 - History or evidence of lung resection, thoracotomy, known aneurysm and severe scoliosis.
 - Pregnancy.

Trial Summary

Enrollment Goal
33
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Ciprofloxacin DPI (BAYQ3939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Gauting, Germany, 82131

Status
Completed
 
Locations

Investigative Site

Hannover, Germany, 30625

Status
Completed
 
Locations

Investigative Site

München, Germany, 81241

Status
Completed
 
Locations

Investigative Site

München, Germany, 80336

Status
Terminated
 
Locations

Investigative Site

Grosshansdorf, Germany, 22927

Status
Completed
 
Locations

Investigative Site

Landsberg, Germany, 86899

Status
Completed
 
Locations

Investigative Site

Frankfurt, Germany, 60596

Status
Completed
 
Locations

Investigative Site

München, Germany, 80539

Status
Completed
 
Locations

Investigative Site

Neu-Isenburg, Germany, 63263

Status
Completed
 
Locations

Investigative Site

Frankfurt, Germany, 60389

Status
Completed
 

Trial Design